UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

 

Date of Report (Date of earliest event reported):       March 21, 2019

 

 

 

VITRO DIAGNOSTICS, INC.
(Exact Name of Registrant as Specified in its Charter)

 

 

       Nevada       

       0-17378       

    84-1012042    

(State or other jurisdiction
of incorporation)

Commission File
Number

(I.R.S. Employer Identification number)

 

 

4621 Technology Drive, Golden CO  80403
(Address of principal executive offices)                    (Zip Code)

 

Registrant's telephone number, including area code:    (303) 999-2130

 

______________________________________________________

(Former name or former address, if changed since last report)

 

 

___

Written communications pursuant to Rule 425 under the Securities Act

___

Soliciting material pursuant to Rule 14a-12 under the Exchange Act

___

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act

___

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company [ X ]  

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    [     ]


 

ITEM 2.02 RESULTS OF OPERATION AND FINANCIAL CONDITION  

ITEM 7.01 REGULATION FD DISCLOSURE  

 

On March 21, 2019, Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, issued a press release announcing its 1 st quarter ended January 31 st 2019 financial results of operations.  The Company recorded 1 st quarter revenues of $192,895 vs $87,185 an increase of 121% over the same comparative quarter last year.  In addition, Stem Cell treatments accounted for 71% of the revenues up from 62% of the revenues in the prior comparative quarter last year.  Current quarter stem cell revenues were $137,123 for the 1 st quarter ended January 31, 2019 vs $54,152 for the first quarter ended January 31, 2018.  A copy of the Press Release is filed herewith as Exhibit 99.1.

The information in this Current Report on Form 8-K furnished pursuant to Item 7.01, including Exhibit 99.1, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liability under that section, and they shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. By filing this Current Report on Form 8-K and furnishing this information pursuant to Item 7.01, The Company makes no admission as to the materiality of any information in this Current Report on Form 8-K, including Exhibit 99.1, that is required to be disclosed solely by Regulation FD.

 

 

ITEM 9.01 : EXHIBITS  

 

 

Item

Title

 

 

 

 

99.1

Press Release

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

Vitro Diagnostics, Inc.
(Registrant)

 

 

 

 

 

Dated:   March 25, 2019

 

/s/ James R. Musick
James R. Musick, President and CEO

 

 

 

 

 

Vitro Diagnostics (PK) (USOTC:VODG)
Historical Stock Chart
From Aug 2020 to Sep 2020 Click Here for more Vitro Diagnostics (PK) Charts.
Vitro Diagnostics (PK) (USOTC:VODG)
Historical Stock Chart
From Sep 2019 to Sep 2020 Click Here for more Vitro Diagnostics (PK) Charts.